Celebrity promotions are nothing new – we see them constantly, from athletes endorsing sports equipment to singers promoting skin care brands.

In June, the Food and Drug Administration (FDA) approved bremelanotide (brand name Vyleesi) to treat a lack of sexual desire in premenopausal women.1 The NWHN advocated against the drug’s approval, and spoke in opposition when the approval announcement was made. Here’s why.  

If you are experiencing low sexual desire, some alternative methods may work better without Addyi's harmful side effects.

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or 425-749-1886

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org

What do you do when your product isn’t popular and sales have slumped? Gin up an advertising campaign to convince consumers that they absolutely have to have what you’re selling.

Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women. Updated: Jul 30, 2019

"My doctor prescribed me Addyi for HSDD. I cannot afford it and my insurance does not cover it. Are there any other resources to get this medication?"